A-Reum Kim, June-Young Koh, Min-Seok Rha, Jae Hyung Jung, Jae-Hoon Ko, Hee Kyoung Choi, Ji Hoon Jeon, Hyeri Seok, Dae Won Park, Kyong Ran Peck, Jun Yong Choi, Su-Hyung Park, Won Suk Choi, Hye Won Jeong, Eui-Cheol Shin
{"title":"Patients With Mild COVID-19 Exhibit Low Functional Avidity of SARS-CoV-2 Membrane Protein-Reactive CD4<sup>+</sup> T Cells.","authors":"A-Reum Kim, June-Young Koh, Min-Seok Rha, Jae Hyung Jung, Jae-Hoon Ko, Hee Kyoung Choi, Ji Hoon Jeon, Hyeri Seok, Dae Won Park, Kyong Ran Peck, Jun Yong Choi, Su-Hyung Park, Won Suk Choi, Hye Won Jeong, Eui-Cheol Shin","doi":"10.4110/in.2025.25.e4","DOIUrl":null,"url":null,"abstract":"<p><p>Herein, we found that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-unexposed individuals exhibited an increased frequency of CD4<sup>+</sup> T cells against SARS-CoV-2 membrane (M) protein, suggesting that SARS-CoV-2 M-reactive cells may be primed by previous infection with common cold coronaviruses (CCCoVs). We confirmed that CCCoV M-reactive CD4<sup>+</sup> T cells cross-recognize SARS-CoV-2 M in unexposed individuals. Among coronavirus disease 2019 (COVID-19) convalescents and unexposed individuals, SARS-CoV-2 M-reactive CD4<sup>+</sup> T cells exhibited significantly lower functional avidity than CD4<sup>+</sup> T cells reactive to other viruses. Importantly, convalescents from mild COVID-19 had SARS-CoV-2 M-reactive CD4<sup>+</sup> T cells with significantly lower functional avidity than convalescents from severe COVID-19. The current data suggest that pre-existing CCCoV M-specific memory CD4<sup>+</sup> T cells may contribute to controlling SARS-CoV-2 infection by cross-reactivity, leading to mild disease but leaving memory cells with low functional avidity to SARS-CoV-2 M due to incomplete homology. These data provide indirect evidence that pre-existing cross-reactive CD4<sup>+</sup> T cells contribute to protection from severe COVID-19.</p>","PeriodicalId":13307,"journal":{"name":"Immune Network","volume":"25 2","pages":"e4"},"PeriodicalIF":4.3000,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12056292/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immune Network","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4110/in.2025.25.e4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Herein, we found that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-unexposed individuals exhibited an increased frequency of CD4+ T cells against SARS-CoV-2 membrane (M) protein, suggesting that SARS-CoV-2 M-reactive cells may be primed by previous infection with common cold coronaviruses (CCCoVs). We confirmed that CCCoV M-reactive CD4+ T cells cross-recognize SARS-CoV-2 M in unexposed individuals. Among coronavirus disease 2019 (COVID-19) convalescents and unexposed individuals, SARS-CoV-2 M-reactive CD4+ T cells exhibited significantly lower functional avidity than CD4+ T cells reactive to other viruses. Importantly, convalescents from mild COVID-19 had SARS-CoV-2 M-reactive CD4+ T cells with significantly lower functional avidity than convalescents from severe COVID-19. The current data suggest that pre-existing CCCoV M-specific memory CD4+ T cells may contribute to controlling SARS-CoV-2 infection by cross-reactivity, leading to mild disease but leaving memory cells with low functional avidity to SARS-CoV-2 M due to incomplete homology. These data provide indirect evidence that pre-existing cross-reactive CD4+ T cells contribute to protection from severe COVID-19.
期刊介绍:
Immune Network publishes novel findings in basic and clinical immunology and aims to provide a medium through which researchers in various fields of immunology can share and connect. The journal focuses on advances and insights into the regulation of the immune system and the immunological mechanisms of various diseases. Research that provides integrated insights into translational immunology is given preference for publication. All submissions are evaluated based on originality, quality, clarity, and brevity